← Tra cứu cổ phiếu
Viewing Quý 1/2026Latest period →

iShareInvest Research

UPCOM · Quý 1/2026

NTF

Dược - Vật tư Y tế Nghệ An

Analysis of business results & financial statements · Quý 1/2026

▲ Slightly positive

See what is changing ↓
P/E
—
P/B
0.91x
EPS
—
BVPS
12,078
ROE
3.6%
ROA
2.6%
Market price
11,000
16 Oct 2026

What Is Changing

On a Năm 2025 basis, NTF has not moved the needle on revenue, but profitability has edged up slightly — margins have been expanding consistently over multiple periods. What remains unclear is whether this improvement can widen without revenue momentum to back it.

A single data point, or a trajectory?

Latest eight quarters · Quý 1/2026

MetricQ1'26
Revenue34.5
LNST-0.2
Net margin-0.65%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins are broadly flat — earnings quality is the factor to watch.

What is driving the margin?

●

Track net margin changes and the operating components against the same period last year.

None

Net Margin
2.28%
+0.9pp
Gross Margin
None
SG&A / Revenue
None
02

Is capital being used efficiently?

Evaluate capital, asset, and working-capital efficiency.

Balance Sheet

●

Balance sheet is exceptionally sound — liabilities at 0.37x equity, with a net cash position equivalent to 0.55x equity.

Inventory ended the period at 29.0bn, roughly 23.2% of total assets.

Over the last 12 months, working capital released 0.0bn of cash.

Working Capital Efficiency

●

Track receivable, inventory, and payable turns to judge working-capital efficiency.

Track DSO, DIO, DPO components to evaluate working capital turnover efficiency.

03

Is financial risk significant?

Financial risk is low — the company has net cash and CFO reached 4.9bn.

Leverage & Liquidity

▲

Track net leverage, interest coverage, and the liquidity buffer on the balance sheet.

At present, cash equals 35513.3% of debt and total debt stands at 0.3bn.

Some leverage signals are missing, so the current read should be treated as contextual.

Net Debt / Equity
−0.55x
Interest Coverage
None
Cash / Debt
35513.3%
Short-term Debt / Total Debt
None

Research synthesis

What this reporting period is showing

The business is showing brightening signals, but the improvement is still early and not yet thick enough to read as a confirmed trend. The brighter spot is balance-sheet flexibility, with net cash/equity at about −0.55x. The next item to monitor is capital structure should be read with cycle risk in mind.

  • Improvement: the balance sheet remains flexible, with a net cash position equivalent to 0.55x of equity.
  • Watchpoint: Capital structure should be read with cycle risk in mind.

Questions for the next period

  1. Ability to stabilize revenue after a −17,8% YoY decline.

  2. Ability to hold margins around the current 2.28% level.

  3. Cash-flow quality, with operating cash flow currently at 4.9bn in 2025.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio